share_log

Pure Extracts Enters Agreement to Acquire PL Healthcare Management

Pure Extracts Enters Agreement to Acquire PL Healthcare Management

Pure Excrates签订收购PL医疗管理协议
Accesswire ·  2023/05/25 15:45

VANCOUVER, BC / ACCESSWIRE / May 25, 2023 / Pure Extracts Technologies Corp. (CSE:PULL)(OTC PINK:PRXTF)(XFRA:A2QJAJ) ("Pure Extracts" or the "Company"), a plant-based extraction company focused on cannabis, hemp and functional mushrooms, is pleased to announce that it has entered into a definitive business combination agreement dated May 1, 2023 (the "Definitive Agreement") with PL Healthcare Management Ltd. ("PLM") and 1411062 B.C. Ltd. ("Subco"), a wholly-owned subsidiary of the Company, pursuant to which the Company will acquire all of the issued and outstanding shares of PLM (the "Transaction").

温哥华,BC/ACCESSWIRE/2023年5月25日/纯提取技术公司(CSE:Pull)(场外粉色:PRXTF)(XFRA:A2QJAJ)(“纯萃取物“或“公司“)、一家专注于大麻、大麻和功能性蘑菇的植物提取物公司高兴地宣布,它已于2023年5月1日签订了一项最终的业务合并协议。最终协议“)与PL Healthcare Management Ltd.(”PLM“)及公元前1411062年有限公司(”Subco),据此,本公司将收购PLM的全部已发行及已发行股份(交易记录“)。

In accordance with the terms and conditions of the Definitive Agreement, the Transaction will be completed by way of a three-cornered amalgamation, whereby, among other things: (a) Subco will amalgamate (the "Amalgamation") with PLM to form an amalgamated company ("Amalco"); (b) each issued and outstanding common share of PLM (of which there are currently 35,301,154) will be exchanged for five (5) common shares of the Company ("Common Shares"); and (c) Amalco will become a wholly-owned subsidiary of the Company. In advance of closing of the Transaction, Pure will carry out a consolidation of its Common Shares on a 10:1 basis (the "Consolidation"), such that, upon the completion of the Transaction, it is expected that existing shareholders of the Company will collectively hold approximately 6.2% of the Common Shares and that former shareholders of PLM will collectively hold approximately 93.8% of the Common Shares.

根据最终协议的条款和条件,交易将以三角合并的方式完成,其中包括:(A)Subco将合并(合并“)与PLM成立一家合并公司(”阿马尔科“);(B)PLM的每股已发行和已发行普通股(其中目前有35,301,154股)将交换为本公司的五(5)股普通股(”普通股);及(C)AMalco将成为本公司的全资附属公司。在交易完成前,Pure将按10:1的比例合并其普通股(“整固“),因此,交易完成后,预计本公司现有股东合共持有约6.2%的普通股,而PLM前股东合共持有约93.8%的普通股。

PLM, an arm's length party to the Company, is a healthcare case management business focused on helping Canadians with health-service case management and related therapies, among other things. Following the completion of the Transaction, the Company plans to utilize cannabis biomass produced by PLM's micro-cultivator and supply its extracted cannabis products to PLM's clients thereby preserving the entire retail sales margin within the Pure Extracts-PLM group of companies. Additionally, Pure Extracts plans to add to its current 47 SKUs by selecting and manufacturing the most beneficial cannabis products from its over 30 proprietary formulations for PLM's clients, addressing such urgent conditions such as PTSD, anxiety and depression.

PLM是该公司的一家独立公司,是一家医疗病例管理公司,专注于帮助加拿大人进行医疗服务病例管理和相关治疗等。交易完成后,该公司计划利用PLM的微型种植机生产的大麻生物质,并将其提取的大麻产品供应给PLM的客户,从而保持Pure Extents-PLM集团公司的整个零售利润率。此外,Pure Exducts计划在其目前的47个SKU的基础上,从其为PLM客户提供的30多种专有配方中挑选和制造最有益的大麻产品,以应对创伤后应激障碍、焦虑和抑郁等紧急情况。

"The PLM team is looking forward to working with Pure Extracts toward strategic development of their business lines and create increasing value for shareholders of both companies," said Shaun Good, the Chief Executive Officer of PLM.

PLM首席执行官肖恩·古德说:“PLM团队期待着与Pure Extras合作,为他们的业务线进行战略发展,并为两家公司的股东创造越来越多的价值。

Ben Nikolaevsky, the Chief Executive Officer and a director of the Company, commented "The combination of the two organizations allows for a synergistic portfolio of products and our ability to reach new segments in the rapidly expanding segment of healthcare and cannabis."

该公司首席执行官兼董事首席执行官本·尼古拉耶夫斯基评论说:“这两个机构的合并使我们能够形成一个协同的产品组合,并使我们有能力进入迅速扩大的保健和大麻领域的新领域。”

Subject to their prior resignation in connection with the Bridge Financing (as defined below), following the completion of the Transaction, and in accordance with the terms of the Definitive Agreement, Ben Nikolaevsky will step down as Chief Executive Officer and a director of the Company and Yana Popova, Sean Bromley and Dwight Duncan will resign from the board of directors of the Company. Shaun Good will be appointed as Chief Executive Officer and a director of the Company and Gerry Abday will be appointed as President and a director of the Company.

在彼等先前因桥融资(定义见下文)而辞职后,在交易完成后,根据最终协议的条款,本·尼古拉耶夫斯基将辞去公司首席执行官兼董事董事一职,雅娜·波波娃、肖恩·布罗姆利和德怀特·邓肯将辞去公司董事会职务。肖恩·古德将被任命为本公司的首席执行官和董事,格里·阿布戴将被任命为总裁和本公司的董事。

The Company also announces a proposed bridge financing (the "Bridge Financing") pursuant to which PLM would advance funds to the Company prior to the completion of the Transaction. The proceeds of the Bridge Financing would be used to permit the Company to execute larger volumes of purchase orders. If completed, a condition of the first advance under the Bridge Financing would be the resignation of up to three (3) existing directors of the Company and their concurrent replacement with three (3) nominees of PLM. It is anticipated that the first advance under the Bridge Financing would be made on or about May 31, 2023.

本公司亦宣布拟进行过渡性融资(“过桥融资“)据此,PLM将在交易完成前向本公司垫付资金。桥梁融资的收益将用于允许公司执行更大数量的采购订单。如果交易完成,桥梁融资项下第一笔垫款的条件将是最多三(3)名公司现有董事辞职,并由三(3)名PLM提名的人同时接替。预计桥梁融资项下的第一笔垫款将在当天或大约5月31日2023年。

Shaun Good has a diverse background in various industries and has demonstrated his leadership and entrepreneurial spirit throughout his career. After founding a successful construction company, he transitioned into a career with a major financial company. Responding to his clients' growing interest in investment opportunities, Shaun entered the cannabis industry in 2017. As the founder of four companies in BC, one of which focuses on the research and development of cannabis cultivars and terpenoids for the medical industry, Shaun demonstrates his relentless pursuit of innovation and commitment to helping others succeed.

肖恩·古德在各个行业有着不同的背景,并在整个职业生涯中展示了他的领导力和创业精神。在创立了一家成功的建筑公司后,他过渡到一家大型金融公司的职业生涯。为了回应客户对投资机会日益增长的兴趣,肖恩于2017年进入大麻行业。作为卑诗省四家公司的创始人,其中一家专注于医疗行业的大麻品种和萜类化合物的研发,肖恩展示了他对创新的不懈追求和帮助他人成功的承诺。

Gerry Abday is a highly accomplished executive with a wealth of experience in the health management and business sectors. As the President of PLM, he has successfully positioned PLM as a leader in the industry by leveraging his keen understanding of market trends and client needs. Gerry's visionary approach to leadership and dedication to excellence has been instrumental in driving the growth and success of PLM. Before taking the helm at PLM, Gerry founded QSD Custom Manufacturing Inc., a thriving business that has generated millions in revenue and served hundreds of clients across North America. Gerry's leadership skills, combined with his passion for improving the lives of others, make him an exceptional figure in both the business world and the wider community. With his vast experience, innovative mindset, and philanthropic spirit, Gerry continues to be a driving force in the pursuit of excellence and positive change.

Gerry Abday是一位非常有成就的高管,在健康管理和商业部门拥有丰富的经验。作为PLM的总裁,他凭借对市场趋势和客户需求的敏锐理解,成功地将PLM定位为行业的领导者。格里富有远见的领导方式和对卓越的奉献精神推动了PLM的发展和成功。在执掌PLM之前,Gerry创立了QSD Custom Manufacturing Inc.,这是一家蓬勃发展的企业,创造了数百万美元的收入,并为北美各地的数百家客户提供服务。格里的领导能力,加上他对改善他人生活的热情,使他在商界和更广泛的社区中都是一个杰出的人物。凭借丰富的经验、创新的心态和慈善精神,格里继续成为追求卓越和积极变革的推动力。

The Transaction will constitute a Fundamental Change of the Company, as such term is defined in the policies of the Canadian Securities Exchange, and completion thereof will be subject to a number of customary conditions precedent, including receipt of required regulatory approvals, approval of the shareholders of the Company, PLM and Subco to the Amalgamation, completion of the Consolidation and the Board Changes.

该交易将构成公司的根本性变化,因为该术语在加拿大证券交易所的政策中有定义,交易的完成将取决于一些惯例的先决条件,包括收到所需的监管批准、获得公司股东的批准、PLM和Subco合并、完成合并和董事会变动。

Trading in the Common Shares has been halted, and will remain halted, pending review and approval of the Transaction by the Canadian Securities Exchange.

普通股的交易已经暂停,并将继续暂停,等待加拿大证券交易所对交易的审查和批准。

About Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)

关于纯提取技术公司(CSE:Pull)(场外交易代码:PRXTF)(XFRA:A2QJAJ)

Pure Extracts features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act on September 25, 2020, and its Sales Amendment on July 19, 2021. The Company's stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020

纯萃取物以全新的、最先进的加工设施为特色,位于世界著名的不列颠哥伦比亚省惠斯勒以北仅20分钟车程。这个定制设施是按照欧盟GMP标准建造的,旨在将产品和配方(包括目前在加拿大受到限制的产品和配方)出口到合法可获得的欧洲司法管辖区。纯萃取物于2020年9月25日根据《大麻法案》获得加拿大卫生部颁发的标准加工许可证,并于2021年7月19日获得其销售修正案的许可。该公司的股票于2020年11月5日在加拿大证券交易所(CSE)开始交易

Find out more at

有关更多信息,请访问

Or contact:
Pure Extracts Investor Relations
Tel: +1 604 493 2052
info@pureextractscorp.com

或联系方式:
纯提取投资者关系
电话:+1 604 493 2052
电子邮箱:Info@pureeartscalp.com

ON BEHALF OF THE BOARD

我代表董事会

"Ben Nikolaevsky"

“本·尼古拉耶夫斯基”

Ben Nikolaevsky
CEO and Director

本·尼古拉耶夫斯基
首席执行官兼董事

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements relating to the Transaction, including statements respecting: the Amalgamation; the timing and potential completion of the Transaction; satisfaction of the conditions precedent to closing of the Transaction; the Consolidation and the expectations of management of the PLM brand; the Company's business and strategic plans; and Bridge Financing by PLM to the Company and the use of such funding, are forward-looking statements and involve risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from what is projected in forward looking statements. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company's expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under "Risk Factors" in the Company's Annual Information Form. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

本新闻稿包含与Pure Extras未来运营有关的前瞻性陈述,其他陈述不是历史事实。前瞻性陈述通常用“将”、“可能”、“应该”、“预期”、“预期”和类似的表达方式来识别。除历史事实陈述外,本新闻稿中包括的所有陈述,包括但不限于与交易有关的陈述,包括与合并有关的陈述;交易的时机和可能完成的陈述;交易完成前条件的满足情况;PLM品牌的整合和管理层的预期;公司的业务和战略计划;以及PLM对公司的过渡性融资和此类资金的使用,均为前瞻性陈述,涉及风险和不确定因素。许多因素可能导致实际事件、业绩或结果与前瞻性陈述中预测的大不相同。尽管我们认为这些陈述背后的假设是合理的,但它们可能被证明是不正确的,我们不能保证实际结果将与这些前瞻性陈述一致。鉴于这些风险、不确定性和假设,投资者不应过度依赖这些前瞻性陈述。无论实际结果、业绩或成就是否符合公司的预期和预测,都会受到许多已知和未知的风险、不确定性、假设和其他因素的影响,包括公司年度信息表格中“风险因素”中列出的那些因素。公司不承诺更新任何前瞻性信息,除非适用的证券法要求更新。

The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release.

加拿大证券交易所既没有批准也没有反对本新闻稿的内容。

SOURCE: Pure Extracts Technologies Corp.

资料来源:纯萃取技术公司


View source version on accesswire.com:
在accesswire.com上查看源代码版本:

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发